5-HT1 Agonist - Pipeline Insight, 2024

This “5-HT1 Agonist - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in 5-HT1 Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

5-HT1 Agonist: Understanding

5-HT1 Agonist: Overview

The 5-HT1A receptor is a major inhibitory G-protein coupled receptor subtype that exists in two major populations in the nervous system (autoreceptor and heteroreceptor), and functions by coupling to Gi/Go proteins that control numerous intracellular signaling cascades, including inhibition of cAMP formation, inactivation of calcium channels, and activation of potassium channels. The 5-HT1A autoreceptor resides on the soma and dendrites of serotonin. The 5-HT1A autoreceptor resides on the soma and dendrites of serotonin neurons in the raphe nuclei, where its activation hyperpolarizes and reduces the firing rate of these cells, and thereby serotonin extracellular levels in its projection areas. Postsynaptic 5-HT1A heteroreceptors are expressed in target areas receiving serotonergic innervation. These heteroreceptors are mainly located on pyramidal neurons and on GABAergic interneurons. Activation of 5-HT1A heteroreceptors in these areas mediates a hyperpolarizing response to released serotonin on pyramidal neurons. 5-HT1A receptors are powerful modulators of 5-HT function through their distinct populations, likely exerting differential effects both by their distinct anatomical localizations as well as by distinct Ga subunit coupling that may account for regional differences in activation versus inhibition of downstream signaling targets.

“5-HT1 Agonist - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the 5-HT1 Agonist pipeline landscape is provided which includes the disease overview and 5-HT1 Agonist treatment guidelines. The assessment part of the report embraces, in depth 5-HT1 Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, 5-HT1 Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence 5-HT1 Agonist R&D. The therapies under development are focused on novel approaches to treat/improve 5-HT1 Agonist.

5-HT1 Agonist Emerging Drugs Chapters

This segment of the 5-HT1 Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

5-HT1 Agonist Emerging Drugs

SEP-363856: Sumitomo Pharma Co., Ltd.SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A).1
SEP-363856 was developed by Sunovion pharmaceuticals. An initial clinical study has shown this drug may be effective against both positive and negative symptoms of schizophrenia. Negative symptoms of schizophrenia are more difficult to treat and may include flattened affect, anhedonia, and social withdrawal. Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug. It is currently being investigated in Phase III clinical trial for the treatment of Schizophrenia.

5-HT1 Agonist: Therapeutic Assessment

This segment of the report provides insights about the different 5-HT1 Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in 5-HT1 Agonist

There are approx. 5+ key companies which are developing the therapies for 5-HT1 Agonist. The companies which have their 5-HT1 Agonist drug candidates in the most advanced stage, i.e. Phase III include, Sumitomo Pharma Co., Ltd.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

5-HT1 Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

5-HT1 Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 5-HT1 Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 5-HT1 Agonist drugs.

5-HT1 Agonist Report Insights

• 5-HT1 Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

5-HT1 Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing 5-HT1 Agonist drugs?
• How many 5-HT1 Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of 5-HT1 Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the 5-HT1 Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for 5-HT1 Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Suven Life Sciences
• Sunovion Pharmaceuticals
• Sumitomo Pharma
• Neurolixis
• Otsuka Pharmaceutical
• Fabre-Kramer Pharmaceuticals

Key Products

• 5-HT1A Agonist
• SEP-363856
• DSP-0038
• NLX-112
• Brexpiprazole
• Travivo

This product will be delivered within 1-3 business days.